home > news > detailed info

CPhI Worldwide: TE-ring remains firmly attached to the dropper bottle in line with FDA requirements

Gerresheimer AG

Niels Düring will be at booth 4.2 D02 at the CPhl, Frankfurt from October 24-26

Düsseldorf/Frankfurt, October 24, 2017 – It is often only minor improvements that make a product ideal to use. The TE-ring fixed to the type A eye-dropper bottle in accordance with the new FDA regulations is one good example.

"It’s often the technical details that add the finishing touches to packaging," says Niels Düring, Global Executive Vice President at Gerresheimer Plastic Packaging, who, with the help of his team, will showcase an extensive portfolio of plastic primary packaging for solids and liquids to existing and potential customers at booth 4.2 D02 at the CPhl in Frankfurt (Germany) from October 24-26.

TE-ring – now firmly attached to the bottle
The US Food and Drug Administration (FDA) now stipulate that the TE-ring must be firmly attached to the bottle. This product change was very easy to make, owing to experience with the type B dropper bottle, which already has a fixed TE-ring. Only minor adjustments were made to the design, while the dimensions, properties, and the materials are the same. The bottle and the dropper are made from LDPE and the cap from HDPE. The existing type A dropper bottles can therefore be used for stability tests.

Production of US dropper bottles with a fixed TE-ring will be operational in Q3, 2017 and production will besides Poland also be produced out of both India and US.

Gerresheimer produces type A dropper bottles holding 2-360 ml under clean-room conditions. Depending on the size of the container, they are produced using the injection blow molding (IBM) or the extrusion blow molding (EBM) process. Radiation or ETO sterilization is possible on request. All caps protect the original contents and can also be supplied with a child-proof screw cap.

You can find more information at

Plastic primary packaging for pharmaceuticals

About Gerresheimer
Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With plants in Europe, North America, South America and Asia, Gerresheimer generates revenues of around EUR 1.4 bn. The company’s comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Press Contact

Jens Kürten
Group Senior Director Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241

Marion Stolzenwald
Senior Manager Corporate Communication
Phone +49 211 6181-246
Fax +49 211 6181-241
phone +49-(0)211/61 81-00
email Klaus-Bungert-Str. 4, 40468 Duesseldorf, Germany
Print this page
Send to a friend
News and Press Releases

Webinar: The Faster Path to Market

On March 22, 2018, SHL Group will hold a live webinar to discuss how pharmaceutical companies can leverage a preconfigured device technology to bring their innovative drug formulations to market more efficiently.
More info >>

White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

Industry Events

BioTrinity 2018

23-25 April 2018, Novotel London West in Hammersmith

BioTrinity 2018 is taking place from 23-25 April at the Novotel London West in Hammersmith. Now in its 12th year, BioTrinity remains the leading life sciences biopartnering and investment conference in Europe, and is a must attend event for R&D companies, TTO’s and academia who are looking to meet, collaborate, partner and seek funding from Big Pharma, Investors and Associated Industry companies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement